NCT06697782 2025-01-22
Aprepitant and Ondansetron Monotherapy or Combination for Postoperative Nausea and Vomiting in Thyroid Cancer
The First Affiliated Hospital of Zhengzhou University
Phase 4 Completed
Clinical Trials
12 trialsNCT05841849 2023-05-03
Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 4 Not yet recruiting
NCT01298193 2023-03-07
Incidence of Chemotherapy-Induced Nausea and Vomiting Associated With Docetaxel-Cyclophosphamide in Early Breast Cancer.
Spanish Breast Cancer Research Group
Phase 4 Completed
NCT01636947 2018-09-25
KMEC
Merck Sharp & Dohme LLC
Phase 4 Completed
NCT02532634 2018-05-11
RAPA
Kangdong Sacred Heart Hospital
Phase 4 Completed
NCT01625455 2017-05-10
Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome
Vanderbilt University Medical Center
Phase 4 Terminated
NCT00092183 2017-05-05
An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071)
Merck Sharp & Dohme LLC
Phase 4 Completed
NCT01432015 2017-03-28
Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting
Gynecologic Oncology Associates
Phase 4 Completed
NCT01913990 2017-01-30
ER11-02
Ottawa Hospital Research Institute
Phase 4 Unknown
NCT02576327 2016-12-30
A Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation
Peking University
Phase 4 Unknown
NCT02347878 2015-01-27
Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH)
Sun Yat-sen University
Phase 4 Unknown
NCT00415103 2009-09-18
AMENO-2
PETHEMA Foundation
Phase 4 Completed